COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Coyle, P., Al-Kanaani, Z., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203965 · Cited by 551
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Chemaitelly, H., Ayoub, H. H., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., Al-Kuwari, E., et al. (2022) · doi:10.1101/2022.02.24.22271440 · Cited by 84
Research works printed but not linked: 9
- Lyngse, 2022.01.28.22270044, Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish households., medRxiv
- Kirsebom, 2022.03.22.22272691, COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England., medRxiv
- Altarawneh, 2022.03.22.22272745, Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar., medRxiv
- Björk, 2022, High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population - first results from a cohort study in Southern Sweden., Infect Dis (Lond), 54, 128, 10.1080/23744235.2021.1982144 · DOI · Paper page
- Kahn, 2022, Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022., Euro Surveill, 27, 10.2807/1560-7917.ES.2022.27.9.2200121 · DOI
- Dean, 2019, Re: "Measurement of vaccine direct effects under the test-negative design"., Am J Epidemiol, 188, 806, 10.1093/aje/kwz019 · doi:10.1093/aje/kwz019
- Inghammar, 2021.08.12.21261981, COVID-19 vaccine uptake among older people in relation to sociodemographic factors –cohort results from southern Sweden., medRxiv
- Eales, 2022.03.29.22273042, The new normal? Dynamics and scale of the SARS-CoV-2 variant Omicron epidemic in England., medRxiv
- Nordström, 2022, Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden., Lancet Infect Dis, 10.1016/S1473-3099(22)00143-8 · DOI · Paper page
Cited by
Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M., Premji, Z., Issa, H., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00801-5 · Cited by 614
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Frankland, T. B., Xie, F., Ackerson, B. K., Valluri, S. R., Jodar, L., & McLaughlin, J. M. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00354-x · Cited by 36
Rahman, M. O., Kamigaki, T., Thandar, M. M., Haruyama, R., Yan, F., Shibamura-Fujiogi, M., Khin Maung Soe, J., Islam, M. R., Yoneoka, D., Miyahara, R., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076892 · Cited by 29
Metadata
- Authors
- Björk, J., Bonander, C., Moghaddassi, M., Rasmussen, M., Malmqvist, U., Inghammar, M., & Kahn, F.
- Venue
- Eurosurveillance
- Published
- 2022-05-05
- Volume
- 27
- Issue
- 18
- ISSN
- 1025-496X (ISSN-L)
- 1560-7917
- OpenAlex
- W4229022258
- Cited by
- 47
- References
- 2
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022. https://app.cochat.ai/papers/10.2807/1560-7917.es.2022.27.18.2200322
- The paper
- Björk, J., Bonander, C., Moghaddassi, M., Rasmussen, M., Malmqvist, U., Inghammar, M., & Kahn, F. (2022). COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022. Eurosurveillance. https://doi.org/10.2807/1560-7917.es.2022.27.18.2200322
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.